Benzo[d]thiazol-2-amine

Names

[ CAS No. ]:
136-95-8

[ Name ]:
Benzo[d]thiazol-2-amine

[Synonym ]:
Benzo[d]thiazol-2-amine
2-Benzothiazolamine
2-Aminobenzothiazole
Benzothiazole-2-ylamine
1,3-Benzothiazol-2-amine
EINECS 205-268-4
MFCD00005785

Biological Activity

[Description]:

Benzo[d]thiazol-2-amine is a favorable ligand to synthesize dinuclear complexes which contain nitrogen heterocycle[1].

[Related Catalog]:

Research Areas >> Others

Signaling Pathways >> Others >> Others

Chemical & Physical Properties

[ Density]:
1.4±0.1 g/cm3

[ Boiling Point ]:
307.5±25.0 °C at 760 mmHg

[ Melting Point ]:
126-129 °C(lit.)

[ Molecular Formula ]:
C₇H₆N₂S

[ Molecular Weight ]:
150.201

[ Flash Point ]:
139.8±23.2 °C

[ Exact Mass ]:
150.025162

[ PSA ]:
67.15000

[ LogP ]:
1.89

[ Vapour Pressure ]:
0.0±0.7 mmHg at 25°C

[ Index of Refraction ]:
1.763

[ Water Solubility ]:
<0.1 g/100 mL at 19 ºC

MSDS

Click to get detail MSDS

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :: DL1050000

CHEMICAL NAME :: Benzothiazole, 2-amino-

CAS REGISTRY NUMBER :: 136-95-8

LAST UPDATED :: 199701

DATA ITEMS CITED :: 5

MOLECULAR FORMULA :: C7-H6-N2-S

MOLECULAR WEIGHT :: 150.21

WISWESSER LINE NOTATION :: T56 BN DSJ CZ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Oral

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: >1 gm/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intraperitoneal

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 200 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

TYPE OF TEST :: LD50 - Lethal dose, 50 percent kill

ROUTE OF EXPOSURE :: Intravenous

SPECIES OBSERVED :: Rodent - mouse

DOSE/DURATION :: 126 mg/kg

TOXIC EFFECTS :: Details of toxic effects not reported other than lethal dose value

MUTATION DATA

TYPE OF TEST :: Mutation in microorganisms

TEST SYSTEM :: Bacteria - Salmonella typhimurium

DOSE/DURATION :: 2500 ug/plate

REFERENCE :: FCTOD7 Food and Chemical Toxicology. (Pergamon Press Inc., Maxwell House, Fairview Park, Elmsford, NY 10523) V.20- 1982- Volume(issue)/page/year: 23,695,1985

Safety Information

[ Symbol ]:

GHS07

[ Signal Word ]:
Warning

[ Hazard Statements ]:
H302

[ Precautionary Statements ]:
P301 + P312 + P330

[ Personal Protective Equipment ]:
dust mask type N95 (US);Eyeshields;Gloves

[ Hazard Codes ]:
Xn:Harmful

[ Risk Phrases ]:
R22;R36

[ Safety Phrases ]:
S26

[ RIDADR ]:
UN 2811 6.1/PG 3

[ WGK Germany ]:
2

[ RTECS ]:
DL1050000

[ Hazard Class ]:
6.1

[ HS Code ]:
2934200090

Synthetic Route

Click to get detail synthetic route

Precursor & DownStream

Precursor

DownStream

Customs

[ HS Code ]: 2934999090

[ Summary ]:
2934999090. other heterocyclic compounds. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%

Articles

Synthesis, antioxidant properties and radioprotective effects of new benzothiazoles and thiadiazoles.

Bioorg. Med. Chem. 17 , 5275-84, (2009)

In this work, we report the synthesis and characterization of new compounds derived from benzothiazoles and thiadiazoles. We observed that structural modifications on these skeletons affected the anti...

Simultaneous determination of benzothiazoles, benzotriazoles and benzosulfonamides by solid phase microextraction-gas chromatography-triple quadrupole mass spectrometry in environmental aqueous matrices and human urine

J. Chromatogr. A. 1338 , 164-73, (2014)

• Benzothiazoles, benzotriazoles and benzosulfonamides determination in aqueous matrices. • New environmental-friendly and high-throughput protocol developed by SPME-GC-QqQMS. • Sample preparation str...

Virtual screening identification of nonfolate compounds, including a CNS drug, as antiparasitic agents inhibiting pteridine reductase.

J. Med. Chem. 54 , 211-221, (2011)

Folate analogue inhibitors of Leishmania major pteridine reductase (PTR1) are potential antiparasitic drug candidates for combined therapy with dihydrofolate reductase (DHFR) inhibitors. To identify n...